TAK – Takeda Pharmaceutical Company Limited
TAK — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
0.19
Margin Of Safety %
5
Put/Call OI Ratio
0.41
EPS Next Q Diff
EPS Last/This Y
48.99
EPS This/Next Y
45.78
Price
17.91
Target Price
18.43
Analyst Recom
2.07
Performance Q
14.92
Upside
-53.1%
Beta
0.04
Ticker: TAK
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-03-02 | TAK | 18.42 | 0.34 | 0.87 | 4133 |
| 2026-03-04 | TAK | 18.22 | 0.36 | 0.04 | 4219 |
| 2026-03-05 | TAK | 17.75 | 0.36 | 3.50 | 4225 |
| 2026-03-09 | TAK | 18.07 | 0.38 | 0.03 | 4200 |
| 2026-03-10 | TAK | 18.2 | 0.40 | 0.81 | 4066 |
| 2026-03-11 | TAK | 18.11 | 0.40 | 14.00 | 4038 |
| 2026-03-12 | TAK | 17.77 | 0.41 | 0.36 | 4066 |
| 2026-03-17 | TAK | 18.39 | 0.42 | 5.20 | 4088 |
| 2026-03-18 | TAK | 18.04 | 0.42 | 2.06 | 4095 |
| 2026-03-19 | TAK | 18.12 | 0.42 | 0.12 | 4100 |
| 2026-03-20 | TAK | 17.82 | 0.42 | 0.18 | 4104 |
| 2026-03-23 | TAK | 17.86 | 0.42 | 1.75 | 3833 |
| 2026-03-24 | TAK | 18.02 | 0.43 | 0.00 | 3851 |
| 2026-03-25 | TAK | 18.3 | 0.42 | 0.05 | 3896 |
| 2026-03-26 | TAK | 18.04 | 0.42 | 0.06 | 3885 |
| 2026-03-27 | TAK | 17.91 | 0.41 | 13.95 | 3990 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | TAK | 18.73 | - | 1183.5 | 49.21 |
| 2026-03-02 | TAK | 18.42 | - | 570.3 | 49.21 |
| 2026-03-03 | TAK | 18.10 | - | 535.8 | 49.21 |
| 2026-03-04 | TAK | 18.22 | - | 582.6 | 49.21 |
| 2026-03-05 | TAK | 17.75 | - | 569.5 | 49.21 |
| 2026-03-06 | TAK | 17.86 | - | 654.1 | 49.21 |
| 2026-03-09 | TAK | 18.07 | - | 544.6 | 49.21 |
| 2026-03-10 | TAK | 18.20 | - | 595.6 | 49.21 |
| 2026-03-11 | TAK | 18.11 | - | 537.4 | 49.21 |
| 2026-03-12 | TAK | 17.77 | - | 730.0 | 49.21 |
| 2026-03-13 | TAK | 17.76 | - | 770.8 | 49.21 |
| 2026-03-17 | TAK | 18.39 | - | 753.6 | 49.21 |
| 2026-03-18 | TAK | 18.04 | - | 664.0 | 49.21 |
| 2026-03-19 | TAK | 18.13 | - | 654.4 | 49.21 |
| 2026-03-20 | TAK | 17.83 | - | 765.3 | 49.21 |
| 2026-03-23 | TAK | 17.87 | - | 773.0 | 49.21 |
| 2026-03-24 | TAK | 18.04 | - | 892.4 | 49.21 |
| 2026-03-25 | TAK | 18.30 | - | 890.2 | 49.21 |
| 2026-03-26 | TAK | 18.04 | - | 774.4 | 49.21 |
| 2026-03-27 | TAK | 17.91 | - | 769.2 | 49.21 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | TAK | 0 | -0.47 | 0.21 |
| 2026-03-02 | TAK | 0 | -0.50 | 0.21 |
| 2026-03-03 | TAK | 0 | -0.50 | 0.21 |
| 2026-03-04 | TAK | 0 | -0.50 | 0.21 |
| 2026-03-05 | TAK | 0 | -0.50 | 0.21 |
| 2026-03-06 | TAK | 0 | -0.50 | 0.21 |
| 2026-03-09 | TAK | 0 | -0.51 | 0.21 |
| 2026-03-10 | TAK | 0 | -0.51 | 0.21 |
| 2026-03-11 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-12 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-13 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-17 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-18 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-19 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-20 | TAK | 0 | -0.51 | 0.22 |
| 2026-03-23 | TAK | 0 | -0.60 | 0 |
| 2026-03-24 | TAK | 0 | -0.60 | 0.22 |
| 2026-03-25 | TAK | 0 | -0.60 | 0.19 |
| 2026-03-26 | TAK | 0 | -0.60 | 0.19 |
| 2026-03-27 | TAK | 0 | -0.60 | 0.19 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.48
Avg. EPS Est. Current Quarter
Avg. EPS Est. Next Quarter
Insider Transactions
Institutional Transactions
-0.6
Beta
0.04
Average Sales Estimate Current Quarter
1115290
Average Sales Estimate Next Quarter
1168500
Fair Value
18.83
Quality Score
64
Growth Score
60
Sentiment Score
81
Actual DrawDown %
5.9
Max Drawdown 5-Year %
-28.9
Target Price
18.43
P/E
74.39
Forward P/E
30.88
PEG
0.73
P/S
1.9
P/B
1.16
P/Free Cash Flow
9.26
EPS
0.24
Average EPS Est. Cur. Y
49.21
EPS Next Y. (Est.)
94.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
2.6
Relative Volume
0.8
Return on Equity vs Sector %
-25.9
Return on Equity vs Industry %
-5.7
EPS 1 7Days Diff
-2
EPS 1 30Days Diff
-24.8
EBIT Estimation
769.2
◆
TAK
Healthcare
$17.91
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
48.2
Range 1M
42.3%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
54%
EPS NY
60.6%
52W%
84.8%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+9232.7% upside
Upside
+9232.7%
Quality
64
MoS
5%
Takeda Pharmaceutical Company LSector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 47455
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba Fiber, Recombinate, Hemofil, Immunate, Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-licensing agreements with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaborations with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Institute, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, and Teva Pharmaceutical Industries; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei, Zedira/Dr. Falk Pharma, Exelixi GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, KM Biologics, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics. The company was founded in 1781 and is headquartered in Tokyo, Japan.
TAK
Latest News
—
Caricamento notizie per TAK…
stock quote shares TAK – Takeda Pharmaceutical Company Limited Stock Price stock today
news today TAK – Takeda Pharmaceutical Company Limited stock forecast ,stock prediction 2023 2024 2025
marketwatch TAK – Takeda Pharmaceutical Company Limited yahoo finance google finance
stock history TAK – Takeda Pharmaceutical Company Limited invest stock market
stock prices TAK premarket after hours
ticker TAK fair value insiders trading